Onchocerciasis in Liberia.

Am J Trop Med Hyg

Published: September 1955

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.1955.4.923DOI Listing

Publication Analysis

Top Keywords

onchocerciasis liberia
4
onchocerciasis
1

Similar Publications

Article Synopsis
  • The study examined the safety and effectiveness of moxidectin versus ivermectin in treating Onchocerca volvulus infections, particularly focusing on microfilariae levels and ocular adverse reactions in patients with high microfilarial counts.
  • Data were collected from 1,463 participants, and results showed that both treatments had similar impacts on ocular microfilariae levels (mfAC) and resulted in Mazzotti reactions in about 10-12% of participants, with factors like gender and pre-treatment mfAC influencing the severity of reactions.
  • The findings suggest that while both treatments are effective, women and those with higher mfAC levels may be at increased risk for more severe ocular reactions post
View Article and Find Full Text PDF

Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?

Philos Trans R Soc Lond B Biol Sci

October 2023

London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.

Epidemiological and modelling studies suggest that elimination of transmission (EoT) throughout Africa may not be achievable with annual mass drug administration (MDA) of ivermectin alone, particularly in areas of high endemicity and vector density. Single-dose Phase II and III clinical trials demonstrated moxidectin's superiority over ivermectin for prolonged clearance of microfilariae. We used the stochastic, individual-based EPIONCHO-IBM model to compare the probabilities of reaching EoT between ivermectin and moxidectin MDA for a range of endemicity levels (30 to 70% baseline microfilarial prevalence), treatment frequencies (annual and biannual) and therapeutic coverage/adherence values (65 and 80% of total population, with, respectively, 5 and 1% of systematic non-adherence).

View Article and Find Full Text PDF

Background: Access to affordable, quality healthcare is the key element of universal health coverage (UHC). This study examines the effectiveness of the neglected tropical disease (NTD) mass drug administration (MDA) campaign approach as a means to deliver UHC, using the example of the Liberia national programme.

Methods: We first mapped the location of 3195 communities from the 2019 national MDA treatment data reporting record of Liberia.

View Article and Find Full Text PDF

Introduction: Delivering preventive chemotherapy through mass drug administration (MDA) is a central approach in controlling or eliminating several neglected tropical diseases (NTDs). Treatment coverage, a primary indicator of MDA performance, can be measured through routinely reported programmatic data or population-based coverage evaluation surveys. Reported coverage is often the easiest and least expensive way to estimate coverage; however, it is prone to inaccuracies due to errors in data compilation and imprecise denominators, and in some cases measures treatments offered as opposed to treatments swallowed.

View Article and Find Full Text PDF

The intersections between NTDs, disability, and mental ill-health are increasingly recognised globally. Chronic morbidity resultant from many NTDs, particularly those affecting the skin-including lymphatic filariasis (LF), leprosy, Buruli ulcer (BU) and onchocerciasis-is well known and largely documented from a medicalised perspective. However less is known about the complex biosocial interaction shaping interconnected morbidities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!